NasdaqGM:KEQU

Stock Analysis Report

Executive Summary

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products.

Snowflake

Fundamentals

Adequate balance sheet average dividend payer.

Risks

  • Kewaunee Scientific has significant price volatility in the past 3 months.
  • Kewaunee Scientific is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Kewaunee Scientific's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.6%

KEQU

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-48.3%

KEQU

9.9%

US Medical Equipment

0.6%

US Market

KEQU underperformed the Medical Equipment industry which returned 9.5% over the past year.

KEQU underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

KEQUIndustryMarket
7 Day1.6%1.1%-0.6%
30 Day4.2%0.6%2.2%
90 Day-11.1%2.9%1.1%
1 Year-46.4%-48.3%10.8%9.9%2.9%0.6%
3 Year-27.8%-33.7%70.1%64.9%44.6%35.2%
5 Year4.2%-9.6%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Kewaunee Scientific's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 month ago | Simply Wall St

Kewaunee Scientific Corporation (NASDAQ:KEQU): Commentary On Fundamentals

Valuation

Is Kewaunee Scientific undervalued based on future cash flows and its price relative to the stock market?

85.97x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Kewaunee Scientific's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Kewaunee Scientific's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Kewaunee Scientific is overvalued based on earnings compared to the US Medical Equipment industry average.

Kewaunee Scientific is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Kewaunee Scientific, we can't assess if its growth is good value.


Price Based on Value of Assets

Kewaunee Scientific is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Kewaunee Scientific expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

18.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Kewaunee Scientific is high growth as no revenue estimate data is available.

Kewaunee Scientific's earnings are expected to grow by 18.3% yearly, however this is not considered high growth (20% yearly).

Unable to compare Kewaunee Scientific's revenue growth to the United States of America market average as no estimate data is available.

Kewaunee Scientific's earnings growth is expected to exceed the United States of America market average.

Kewaunee Scientific's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Kewaunee Scientific will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Kewaunee Scientific performed over the past 5 years?

0.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Kewaunee Scientific's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.

Kewaunee Scientific's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Kewaunee Scientific's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.


Return on Equity

Kewaunee Scientific has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Kewaunee Scientific used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Kewaunee Scientific's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Kewaunee Scientific's financial position?


Financial Position Analysis

Kewaunee Scientific is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Kewaunee Scientific's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Kewaunee Scientific's level of debt (29.7%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (27.4% vs 29.7% today).

Debt is well covered by operating cash flow (34.5%, greater than 20% of total debt).

Interest payments on debt are not well covered by earnings (EBIT is 2.9x annual interest expense, ideally 3x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 4.8x debt.


Next Steps

Dividend

What is Kewaunee Scientific's current dividend yield, its reliability and sustainability?

4.75%

Current Dividend Yield


Dividend Yield and Payments Analysis

Kewaunee Scientific's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

Kewaunee Scientific's dividend is above the markets top 25% of dividend payers in United States of America (3.71%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are not well covered by earnings (0.2x coverage).


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Kewaunee Scientific's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Thomas Hull (43yo)

0.5yrs

Tenure

US$403,701

Compensation

Mr. Thomas D. Hull, III, has been President and Chief Executive Officer at Kewaunee Scientific Corporation since March 11, 2019 and served as its Chief Financial Officer since November 1, 2015 until April  ...


CEO Compensation Analysis

Thomas's remuneration is about average for companies of similar size in United States of America.

Thomas's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.4yrs

Average Tenure

50yo

Average Age

The tenure for the Kewaunee Scientific management team is about average.


Board Age and Tenure

5.3yrs

Average Tenure

63yo

Average Age

The tenure for the Kewaunee Scientific board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$4,96718 Mar 19
Ryan Noble
EntityIndividual
Shares232
Max PriceUS$21.41

Ownership Breakdown


Management Team

  • Kurt Rindoks (61yo)

    Vice President of Product Development & International Sourcing

    • Tenure: 23yrs
    • Compensation: US$223.18k
  • Keith Smith (50yo)

    Director of Metal Plant Operations and Facilities

    • Tenure: 3.4yrs
    • Compensation: US$260.43k
  • Elizabeth Phillips (42yo)

    Vice President of Human Resources

    • Tenure: 10.3yrs
  • Sathya Sathyamurthy (50yo)

    MD of International Operations & VP of Kewaunee Scientific Corporation Singapore Pte. Ltd.

    • Tenure: 0yrs
  • Thomas Hull (43yo)

    President

    • Tenure: 0.5yrs
    • Compensation: US$403.70k
  • Mike Rok (53yo)

    Vice President of Manufacturing Operations

    • Tenure: 3.3yrs
    • Compensation: US$312.29k
  • Don Gardner (40yo)

    VP of Finance

    • Tenure: 0.4yrs

Board Members

  • Keith Gehl (60yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: US$91.99k
  • David Rhind (56yo)

    Chairman

    • Tenure: 0.6yrs
    • Compensation: US$90.13k
  • Margaret Pyle (67yo)

    Director

    • Tenure: 24.6yrs
    • Compensation: US$83.25k
  • Don Shaw (68yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$87.00k
  • John Russell (66yo)

    Director

    • Tenure: 8.3yrs
    • Compensation: US$89.50k
  • Thomas Hull (43yo)

    President

    • Tenure: 0.5yrs
    • Compensation: US$403.70k

Company Information

Kewaunee Scientific Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kewaunee Scientific Corporation
  • Ticker: KEQU
  • Exchange: NasdaqGM
  • Founded: 1906
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$44.002m
  • Shares outstanding: 2.75m
  • Website: https://www.kewaunee.com

Number of Employees


Location

  • Kewaunee Scientific Corporation
  • 2700 West Front Street
  • Statesville
  • North Carolina
  • 28677
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KEQUNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 1980

Biography

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products. The company operates in two segments, Domestic and International. Its products  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 23:38
End of Day Share Price2019/09/20 00:00
Earnings2019/07/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.